Comparison of the effects of marchantin C and fucoidan on sFlt-1 and angiogenesis in glioma microenvironment

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 4, 2012, Pages 604-609

  Lv, Yafeng ^a   Song, Qingxu ^b   Shao, Qianqian ^b   Gao, Wenjuan ^b   Mao, Haiting ^b   Lou, Hongxiang ^b   Qu, Xun ^b   Li, Xingang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

anti angiogenesis; fucoidan; glioma; marchantin C; sFlt 1

Indexed keywords

ANGIOGENESIS INHIBITOR; FUCOIDIN; MARCHANTIN C; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; ENDOTHELIAL CELL TUBE FORMATION ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MONOCYTE; PROTEIN DEPLETION; PROTEIN SECRETION; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; CELL LINE; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIOMA; HUMANS; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; PHENYL ETHERS; POLYSACCHARIDES; TUMOR MICROENVIRONMENT; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84862815238     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01430.x     Document Type: Article

References (33)

1. Ohgaki H,. Epidemiology of brain tumors. Methods Mol Biol 2009; 472: 323-342.
2. Kleihues P, et al,. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000.
3. Hoeben A, et al,. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56: 549-580. (Pubitemid 39658463)
4. Schmidt NO, et al,. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999; 84: 10-18. (Pubitemid 29059101)
5. Stockmann C, et al,. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008; 456: 814-818.
6. Jain RK,. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989. (Pubitemid 32937367)
7. Winkler F, et al,. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-563. (Pubitemid 40017699)
8. Cloughesy T, et al,. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 2008; 26 (Suppl. 15): 2010b.
9. Eremina V, et al,. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136. (Pubitemid 351398487)
10. Friedman HS, et al,. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
11. Kendall RL, Thomas KA,. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709. (Pubitemid 23347111)
12. Hornig C, et al,. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000; 80: 443-454. (Pubitemid 30226626)
13. Olsson AK, et al,. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
14. Tanaka K, et al,. Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn J Cancer Res 1997; 88: 867-876. (Pubitemid 27475089)
15. Kendall RL, et al,. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324-328. (Pubitemid 26331903)
16. Karumanchi SA, Bdolah Y,. Hypoxia and sFlt-1 in preeclampsia: the 'chicken-and-egg' question. Endocrinology 2004; 145: 4835-4837. (Pubitemid 39551099)
17. Chahal M, et al,. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol 2010; 12: 822-833.
18. Lamszus K, et al,. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 2003; 9: 1399-1405. (Pubitemid 36418393)
19. Takano S, et al,. Angiogenesis and antiangiogenic therapy for malignant gliomas. Brain Tumor Pathol 2004; 21: 69-73. (Pubitemid 39518149)
20. Goldman CK, et al,. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998; 95: 8795-8800. (Pubitemid 28350568)
21. Harding TC, et al,. AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. Mol Ther 2006; 13: 956-966.
22. Bodempudi V, et al,. Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors. Cancer Gene Ther 2010; 17: 855-863.
23. Schwartner C, et al,. Marchantins and related polyphenols from liverwort: physico-chemical studies of their radical-scavenging properties. Free Radic Biol Med 1996; 20: 237-244. (Pubitemid 26025482)
24. Niu C, et al,. Antifungal bis[bibenzyls] from the Chinese liverwort Marchantia polymorpha L. Chem Biodivers 2006; 3: 34-40. (Pubitemid 43154282)
25. Asakawa Y,. Recent advances of biologically active substances from the marchantiophyta. Nat Prod Commun 2008; 3: 77-92.
26. Shi YQ, et al,. Marchantin C, a novel microtubule inhibitor from liverwort with anti-tumor activity both in vivo and in vitro. Cancer Lett 2009; 276: 160-170.
27. Shi YQ, et al,. Marchantin C, a macrocyclic bisbibenzyl, induces apoptosis of human glioma A172 cells. Cancer Lett 2008; 262: 173-182.
28. Shen J, et al,. Marchantin C: a potential anti-invasion agent in glioma cells. Cancer Biol Ther 2010; 9: 33-39.
29. Chizhov AO, et al,. A study of fucoidan from the brown seaweed Chorda filum. Carbohydr Res 1999; 320: 108-119. (Pubitemid 29430291)
30. Bilan MI, et al,. Structure of a fucoidan from the brown seaweed Fucus evanescens C.Ag. Carbohydr Res 2002; 337: 719-730. (Pubitemid 34304181)
31. Li B, et al,. Fucoidan: structure and bioactivity. Molecules 2008; 13: 1671-1695.
32. Do H, et al,. Suppression of iNOS expression by fucoidan is mediated by regulation of p38 MAPK, JAK/STAT, AP-1 and IRF-1, and depends on up-regulation of scavenger receptor B1 expression in TNF-alpha- and IFN-gamma-stimulated C6 glioma cells. J Nutr Biochem 2010; 21: 671-679.
33. Lu ZQ, et al,. Terpenoids and bisbibenzyls from Chinese liverworts Conocephalum conicum and Dumortiera hirsuta. J Asian Nat Prod Res 2006; 8: 187-192.